banda transcan 2 2016ul

Title: Improving immunotherapy of solid tumors by targeting the immunosuppressive tumor microenvironment: from pre-clinical proof-of-concept to the development of phase Ib study


Project Coordinator:
Massimo DI NICOLA (Italy) Fondazione IRCCS, Istituto Nazionale Tumori, Medical Oncology, Milano


Project Partners:
François GHIRINGHELLI (France) Department of Medical Oncology, Center Georges François Leclerc, Dijon
Pedro BERRAONDO (Spain) Immunology and Immunotherapy Programme, Center for Applied Medical Research. University of Navarra, Pamplona
Pei-Jen Alex LOU (Taiwan) Department of Otolaryngology National Taiwan University Hospital  and  National Taiwan University College of Medicine, Taipei
Wojciech GOLUSINSKI (Poland) Department of Head and Neck Surgery Poznan University of Medical Sciences, The  Greater  Poland  Cancer Centre, Poznan


Project Abstract:
Background – Immunotherapy with immune checkpoint blockers (ICB) is effective against several malignancies, but only a fraction of patients achieve clinical benefit. Identification of innate resistance mechanisms is crucial to improve the rate of response.
Hypothesis – Assessment and pre-clinical targeting of main immunosuppressive mechanisms in the tumor microenvironment (TM) may lead to more effective immunotherapeutic combinations.
Aims – 1. A retrospective bio-molecular characterization of immunosuppressive cells and matricellular proteins in TM of 4 tumors (triple negative breast cancer, TNBC; head and neck, HNSCC; melanoma and colorectal cancer, CRC). The immunosuppressive TM will be evaluated even in pre e post-chemotherapy (CT) lesions from patients receiving neoadjuvant therapy; 2. exploit mouse models for testing synergistic anti-tumor activity of ICB combined with drugs targeting the immunosuppressive TM. Combinations will be based on results from Aim 1 as well as on available off-the-shelf drugs known to target the TM; 3. To design phase Ib clinical study in TNBC, HNSCC, melanoma and CRC assessing activity of ICB associated with microenvironment modulators chosen according to results of Aim 1 and 2.
Methods - TM will be analyzed by IHC, multi-parametric fluorescence-based digital pathology analysis, flow cytometry in freshly isolated surgical specimens, qPCR on FFPE tissues and interrogation of gene expression data. Models based on transplantable and spontaneous tumors will be used to test the activity of radiotherapy and drugs known to target immunosuppressive cells and matricellular proteins. According to the preclinical data, phase Ib study will be designed in order to verify the safety of combo approaches.
Expected results – Pre-clinical and early clinical results supporting the development of advanced immunotherapy approaches based on concurrent targeting of immune checkpoints and of relevant immunosuppressive mechanisms.

Final Publishable Summary:
Background- Immunotherapy with immune checkpoint blockers (ICB) is effective against several  malignancies, but only a fraction of patients achieves clinical benefit. Identification of innate resistance mechanisms is crucial to improve the rate of response.
Hypothesis
– Assessment and pre-clinical targeting of main immunosuppressive mechanisms in the tumor microenvironment (TM) may lead to more effective immunotherapeutic combinations.
Aims

  1. A retrospective bio-molecular characterization of immunosuppressive cells and matricellular proteins in TM of four tumors, triple negative breast cancer (TNBC), head and neck (HNSCC), melanoma and colorectal cancer (CRC). The immunosuppressive TM will be evaluated even in pre- and post-chemotherapy (CT) lesions from patients receiving neoadjuvant therapy; 2. exploit mouse models for testing synergistic anti-tumor activity of ICB combined with drugs targeting the immunosuppressive TM. Combinations will be based on results from Aim 1 as well as on available off-the-shelf drugs known to target the TM; 3. To design phase Ib clinical study in TNBC, HNSCC, melanoma and CRC assessing activity of ICB associated with microenvironment modulators chosen according to results of Aim 1 and

Methods - TM will be analyzed by IHC, multi-parametric fluorescence-based digital pathology analysis, flow cytometry in freshly isolated surgical specimens, qPCR on FFPE tissues and interrogation of gene expression data. Models based on transplantable and spontaneous tumors will be used to test the activity of radiotherapy and drugs known to target immunosuppressive cells and matricellular proteins.
Expected results
– Pre-clinical results supported the analyses of gene expression data to discriminate patients that could be directly treated with ICIs from those for which the chemotherapy is required to convert the immunosuppressive microenvironment. In particular, the discovery of novel targets whose expression is deregulated following standard chemotherapy, offered the possibility to target in a more specific way the immunosuppressive environment responsible for treatment failure.



(Project selected for funding under JTC 2015)


TRANSCAN News

 TRANSCAN-3 news on:
twitter logoinkedin social media logo

TRANSCAN-3   JOINT TRANSNATIONAL CALL 2022 on:
 "Novel translational approaches to tackle the challenges of hard-to-treat cancers from early diagnosis to therapy"  

is open for submission

Please visit the TRANSCAN-3 website at
https://transcan.eu/funding/calls/joint-call-jtc-2022-.kl


Other news:

The Digital Institute for Cancer Outcomes Research (DIGICORE),  is delighted to announce an innovative new training programme for early career researchers in oncology: IDEAL4RWE.
 Please register for an introductory webinar on the19th April 2022(https://lnkd.in/ez7y4kWU).
Brochure for more details: https://tinyurl.com/y7aurdtk


 The first TRANSCAN-3 call (JTC 2021) on:
"Next generation cancer immunotherapy: targeting the tumour microenvironment"
is closed for submission

International Networking Event (virtual)
on 22 April 2021 hrs 9:00 CET
will focus on the forthcoming co-funded JTC 2021 on:
"Next generation cancer immunotherapy: targeting the tumour microenvironment" 
the event is organized by TUBITAK under the “Turkey in Horizon 2020 Phase II” Technical Assistance Project
in cooperation with TRANSCAN-3

The new ERA-NET Cofund TRANSCAN-3:
 Sustained collaboration of national and regional programmes in cancer research
is funded by the European Commission under H2020  which started on 1st March 2021 and will last five years (G. A. no. 964264)

A TRANSCAN-2 brochure, highlighting key achievements, is available for download

 

Newsletters

The TRANSCAN-3 newsletters are published at: https://www.transcan.eu/

SUBSCRIBE to the newsletters
You can unsubscribe at any moment by clicking on the subscription preferences link at the bottom of a received newsletter


All the TRANSCAN-2 newsletters:

Newsletter 10, Sept.2020
Newsletter 9, Dec.2019

Newsletter 8, May 2019
Newsletter 7, Oct.2018
Newsletter 6, June 2108
Newsletter 5, March 2018
Newsletter 4, Dec. 2017
Newsletter 3, Sept. 2017
Newsletter 2, April 2017
Newsletter 1, Dec. 2016

eu flagship

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 643638.

Who's Online

We have 7 guests and no members online